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A B S T R A C T
Objective: Fenugreek (Trigonella foenum-graecum) is a medicinal plant from Fabaceae family. This clinical
study was designed to evaluate the effects of Fenugreek seeds supplementation on serum biochemical
parameters of patients with borderline hyperlipidemia.
Materials and methods: A randomised, double-blind, placebo-controlled clinical trial was conducted on 56
patients with borderline hyperlipidemia that were divided in two groups: F group received 8 g Fenugreek
seeds powder sachets and P group received placebo sachets daily for 8 weeks. After 2 months,
triglycerides (TG), total cholesterol (TC), low-density lipoprotein (LDL), high-density lipoprotein (HDL),
fasting blood glucose (FBG) and body mass index (BMI) were evaluated and compared with the baseline.
Results: After 2 months, TG, TC, LDL and FBG signiﬁcantly decreased in F group in comparison with P
group, but these changes were not signiﬁcant in HDL and BMI.
Conclusion: Our ﬁndings showed that Fenugreek seeds supplementation, as a phenolic-rich herb can be
effective in the reduction of some lipid proﬁle in patients with borderline hyperlipidemia.
© 2017 Elsevier Ltd. All rights reserved.
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Dyslipidemias, a kind of disorder of lipid metabolism, are
common worldwide and are characterised by increased plasma
levels of the various lipid and lipoprotein fractions including total
cholesterol and low-density lipoprotein (LDL), very low-density
lipoprotein (VLDL), triglycerides, chylomicrons and their effects on
cardiovascular disorders [1].
Hypercholesterolemia and the level of LDL have an important
role in development of cardiovascular disease (CVD) and the
reduction thereof can assist in the management of cardiovascular
disease. Despite the diverse lipid-lowering drugs such as statins (3-
hydroxy-3-methylglutaryl coenzyme A reductase) for the controlAbbreviations: BMI, body mass index; CVD, cardiovascular disease; FBS, fasting
blood sugar; HDL, high density lipoprotein; LDL, low-density lipoprotein; TG,
triglycerides; SCFAs, short-chain fatty acids; TCH, total cholesterol; VLDL, very low-
density lipoprotein.
* Corresponding author at: Department of Horticultural Sciences, Science and
Research Branch, Islamic Azad University, Tehran, Iran.
E-mail address: hrardalani@srbiau.ac.ir (H. Ardalani).
http://dx.doi.org/10.1016/j.aimed.2016.12.002
2212-9588/© 2017 Elsevier Ltd. All rights reserved.of hyperlipidemia, a signiﬁcant number of patients do not reach
their LDL target points and the side effects of these drugs have been
reported in some studies [2–4]. To expedite the reduction of LDL
cholesterol, higher doses of statins can be administered. However,
even with high doses of statins, atherogenic dyslipidemia is not
completely reversed. For this reason, other approaches to the
treatment of combined hyperlipidemia may be considered [5]. On
the other hand, in recent years, herbal medicines such as Melissa
ofﬁcinalis, Silybum marianum, Anethum graveolens and Rhus coriaria
have been used for management of hyperlipidemia [6–8].
Nowadays, there is an increase in the interest in dietary bioactive
compounds that protect humans against several diseases and/or
reduce their intensity [9]. Fenugreek (Trigonella foenum-graecum)
belongs to Fabaceae family. It is a highly antioxidant and phenolic-
rich food that contains ﬂavonoids, such as kaempferol 3-O-
glycoside, apigenin-7-O-rutinoside, and naringenin. The effects of
these phenolic compounds in hyperlipidemia have been demon-
strated in the literature [10,11]. Therefore, studies aimed to ﬁnd
complementary and alternative way to treatment diseases with
much more efﬁcacy and less adverse effects for normalisation of
lipid proﬁle seems to be essential.
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2.1. Study design
A parallel, randomised, double-blind and placebo-controlled
clinical trial was conducted, with the participation of 56 patients
with hyperlipidemia (conducted in Besat Nahaja Hospital, Tehran,
Iran between January and March 2014). This study was approved
by Medical Ethics Commission in Qazvin University of Medical
Sciences and registered in the Iranian Registry of Clinical Trials at
(http://www.irct.ir) with the IRCT2013111815452N1 and reported
as CONSORT criteria. This study was conducted in accordance with
the Declaration of Helsinki.
2.2. Plant extraction and bioactive screening
For the Fenugreek powder extract, 100 g of Fenugreek sachets
were weighed and water:methanol (30:70) was added. The
solution was stirred at 100 rpm for 24 h at room temperature.
Then, the extract was ﬁltered by paper, transferred into a ﬂask and
dried using a rotating evaporator at 40 C. Finally, extract was
stored at 6 C to prevent compound degradation until analysis. The
Folin-Ciocalteu technique was used for total phenol content
characterisation [12]. Therefore, 50 mL of extract was assayed
with 250 mL of Folin reagent and 500 mL of Na2CO3 (20%, w/v). The
mixture was diluted with double distilled water to obtain ﬁnal
volume of 5 mL. Finally, the extract was incubated for 1 h at 27 C
and was then measured at 765 nm by a spectrophotometer. Gallic
acid, as a standard, was used for concentration calculating and the
results were expressed as gallic acid equivalents per gram of
extract.
2.3. GC-MS analysis of Fenugreek seeds
Analyses were carried out on a Hewlett-Packard 5890 Series II
included gas chromatograph interfaced to a Hewlett Packard
5989B mass spectrometer. Separations were performed on Ultra 1
(49 m 0.20 mm I.D., 0.11 mm, Hewlett-Packard) and DB-Wax (60 m
0.25 mm I.D., 0.25 mm) capillary columns. Helium was used as a
carrier gas (1.0 mL/min C.F.) and the oven temperature was
programmed as 65–230 C with a heating rate of 2 C/min.
Injector and interface temperatures were 230 C and 250 C,
respectively. EI mass spectra were recorded at 70 V ionisation
voltages over the mass range 40–400. Samples (0.5 mL of oil
solutions 1:10 in hexane) were injected by split injection (1:33).
2.4. Inclusion criteria
The inclusion criteria: greater than 18 years and less than 65
years old; an experiment with one of the following factors related
to dyslipidemia: LDL >135 mg and <190 mg/dl; high density
lipoprotein (HDL) <40 mg/dl; total cholesterol (TCH) >200 mg/dl;
triglyceride (TG) >150 mg/dl.
2.5. Exclusion criteria
The exclusion criteria: having underlying diseases such as
diabetes, ischaemic heart disease (IHD), hypertension, metabolic
syndrome, peripheral vascular disease, history of coronary artery
disease; patients who used anti-hyperlipidemic agents, steroids;
cigarette; alcohol; the patients with LDL level 190 mg/dl that
need to medical treatment (for healthy people or with one risk
factor); patients who may undergo unpleasant complications
during the study including headache, vertigo, nausea and
Fenugreek intolerance.2.6. Drug design
The 8 g of Fenugreek seeds sachets were provided from Dineh
Pharmaceutical Company, Tehran, Iran and the sachets containing
starch as placebo in the same shape, size and colour were prepared
by a pharmacist and packed in the same style container with a
code. All sachets obtained either 8 g with the powder of Fenugreek
or 8 g starch. Moreover, all containers were labelled as A or B.
2.7. Randomisation
The randomisation allocation sequence was generated by a
statistician with SAS 9.2 statistical software PROC PLAN. The
statistician for the randomisation did not participate in the study.
Because all participants received both interventions (F and P
groups), limitation such as blocking were unnecessary. Subjects
complying with selection criteria were assigned a randomisation
number taken from a randomisation list following the chronologi-
cal order by which they were included, after verifying compliance
with inclusion and exclusion criteria. The randomisation list
remained closed until the end of the experimental intervention
and registering data had ﬁnished. Blinding was sustained using
matching placebo sachets that did not differ from the F sachets
with regard to appearance or any other physical characteristics. All
sachets were presented in opaque pack plastic packaging, and were
delivered face-to-face at the beginning of each intervention period
by the physician. The kind of drugs or placebo was not recognisable
for patient or administrative of this study. Compliance treatment
monitoring was measured with a questionnaire ﬁlled in by patients
at a clinical interview, and the sachets bag bottles were returned
afterwards. Consumption of >85% was considered an acceptable
level of adherence.
2.8. Interventions
All the 56 patients were divided into 2 groups randomly:
Fenugreek group (F group) and placebo group (P group) through
sortation cards, in randomised and blind fashion (Fig. 1). The F
group obtained Fenugreek sachets (8 g of Fenugreek seed powder,
Dineh Pharmaceutical Company, Tehran, Iran) and P group
received placebo sachets (8 g starch powder) with the lunch
meals for 8 weeks (the usage of drugs was explained for each
patient individually). The patients followed up to control in terms
of use sachets, response to the relevant questions, and prevention
of sample loss and to receive sachets for the next month was done
via monitoring the patients referring to Besat Nahaja Hospital.
Likewise, the participants were advised to not change their usual
diet, self-reliant changes of their drugs doses and physical
activities during the intervention and use of other same products.
2.9. Measurements
Demographic data including age, BMI, gender, marital status,
medical and drug history were evaluated and recorded through
interview at the baseline and 8 weeks after the intervention with
the patients. The patients’ weight by a scale with 100 g error and
with light clothing, height, in standing position without shoes by a
height-measurer with 1 cm error were measured before and 8
weeks after study and calculated BMI with relevant formula. After
12–14 h of fasting, 10 mL sample of venous blood was taken from
each patient by laboratory technician at baseline and end of the
intervention. The centrifuge of samples was performed at the room
temperature and at 3000 rpm for 10 min to separate serum. FBG
was assessed using an enzymatic (glucose oxidise-peroxides) in
vitro test. Serum total cholesterol, TG, LDL and HDL levels were
measured by enzymatic colorimetric analysis. All of tests used
Fig. 1. Flow chart of the study participants.
Table 1
Chemical compounds detected in Fenugreek by GC/MS.
No. Compounds RIa % %
1 Germacrene-D 1461 28.2
2 Bicyclogermacrene 1508 27.1
3 Viridiﬂorol 1563 5.9
4 b-caryophyllene 1409 5.6
5 Spathulenol 1561 4.1
6 Carvone 1260 2.5
7 Allo-aromadendrene 1459 2
8 Ledol 1611 1.9
9 Caryophyllene oxide 1561 1.4
10 a-cadinol 1672 1.4
11 d-cadinene 1529 1.2
12 b-elemene 1403 1.1
13 b-bourbonene 1381 1
14 n-dodecane 1197 1
15 terpinene-4-ol 1204 0.9
16 valeranone 1692 0.8
17 a-pinene 933 0.7
18 Trans-b-ionone 1499 0.5
19 a-thujone 1110 0.4
20 a-terpineol 1189 0.4
21 Tau-muurolol 1644 0.3
22 Mintsulﬁde 1737 0.3
23 b-copaene 1420 0.3
24 a-copaene 1411 0.3
25 Bornylacetate 1309 0.3
26 Palustrol 1563 0.2
27 n-tetradecane 1431 0.2
28 Borneol 1161 0.2
29 Heptadecane 1692 0.1
30 Limonene 1067 0.1
a RI, retention Kovats indices.
Table 2
Baseline characteristics of patients in Fenugreek and placebo groups.
Variables F group P group P-value
Mean  SD Mean  SD
Age (year) 37.22  11.73 38.07  11.79 0.79
TG mg/dl 209.75  81.92 208.11  103.46 0.95
TC mg/dl 208.33  27.20 210.89  53.11 0.76
LDL mg/dl 123.82  33.46 135.89  41.63 0.12
HDL mg/dl 41.19  7.66 42.89  10.13 0.84
FBS mg/dl 95.52  5.91 96.33  11.02 0.25
LDL/HDL 2.96  0.78 2.16  0.80 0.19
TCH/HDL 5.057  0.16 3.87  1.07 0.06
BMI kg/m2 27.42  3.46 27.59  2.28 0.81
Gender N (%) N (%)
Female 11 (45.8) 12 (48) 0.68
Male 13 (54.2) 13 (52)
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2.10. Sample size
To detect differences between the two interventions (F and P
groups) of TC 20 mg/dl under a = 0.05 bilateral signiﬁcance level,
power of study 85% and the sample size was 49 participants.
2.11. Statistical analysis
Statistical analysis was performed with SPSS version 21 (SPSS
Inc., Chicago, IL, USA). For determining of quantitative data
distribution, Kolmogorov–Smirnov test was used. The results of
the quantitative data with normal distribution were reported as
mean  SD. Paired samples t-test was applied to identify the
differences between the conditions before and after measure-
ments and two independent samples t-test was used for the
analysis of differences between the groups. P-values 0.05 were
considered signiﬁcant.
2.12. Results
After the GC-MS analysis of Fenugreek seeds essential oils, 30
chemical compounds were identiﬁed in this herb (Table 1). The
most abundant constituents in this plant were germacrene-D,
bicyclogermacrene, viridiﬂorol and b-caryophyllene with 28.2,
27.1, 5.9 and 5.6 percentages. The extract analysis in this herb
indicated that the polyphenols includes most abundant constit-
uents of this plant (112.7 mg gallic acid equivalents/g dry weight
extracts). Among the study, 7 patients (out of 56) had left the study
according to personal reasons. Finally, 49 participants completed
this study that 24 patients in F group including: 11 females (45.8%)
and 13 males (54.2%) and 25 patients in P group including: 12females (48%) and 13 males (52%) accomplished this trial. The
average ages in this study were 37.22 y  11.73 y and 38.07 y
 11.79 y in F and P group, respectively. The baseline LDL, HDL, TCH,
TG, FBS, BMI, LDL: HDL and TCH:HDL in two groups were assessed
with no signiﬁcant differences between the two groups (P  0.05)
(Table 2). Biochemical parameters of participants in F and P groups
including FBS, LDL, HDL, TC, TG, LDL:HDL, TCH: HDL and BMI have
been shown at the baseline and the end of study (Table 3). The
results of this intervention showed a signiﬁcant difference in TG
and FBS (P  0.05), LDL (P  0.01) and TCH (P  0.001) between two
groups after the study, but there were no signiﬁcant differences
between two groups in HDL, TCH: HDL, LDL: HDL and BMI
(P  0.05). There were signiﬁcantly reductions in TG, LDL, FBS and
TC in F treated vs. placebo group after 8 weeks when compared
Table 3






Before After Before After
TG 209.75  81.92 202.2  83.09 0.042* 208.11  103.46 207.04  38.16 0.062
TCH 208.33  27.20 206.32  19.12 0.003*** 210.89  53.11 211.32  34 0.96
LDL 123.82  33.46 129.74  26.71 0.01** 135.89  41.63 135.84  25.67 0.16
HDL 41.19  7.66 41.54  7.86 0.65 42.89  10.13 43.71  9.54 0.46
FBS 95.52  5.91 93.13  2.3 0.04* 96.33  11.02 95.85  10.15 0.32
LDL/HDL 2.96  0.78 2.97  0.66 0.91 2.16  0.80 2.24  0.73 0.43
TCH/HDL 5.057  0.16 5.04  0.88 0.9 3.87  1.07 3.74  0.95 0.36
BMI 27.42  3.46 27.28  3.32 0.25 27.59  2.28 27.43  2.37 0.18
BMI, body mass index; FBS, fasting blood sugar; HDL, high-density lipoprotein; LDL, low-density lipoprotein; TCH, total cholesterol; TG, triglyceride.
* Signiﬁcant in P  0.05.
** Signiﬁcant in P  0.01.
*** Signiﬁcant in P  0.001.
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2.01 mg/dl in TG, LDL, FBS and TC, respectively compared with
baseline. However, such an effect was not observed in the P group.
Although the reductions in HDL, TCH: HDL, LDL: HDL and BMI was
not signiﬁcant (P  0.05).
3. Discussion
In many hyperlipidemic patients, maintaining lipid proﬁles in
an optimal range is difﬁcult and prescribing several drugs from
different pharmacological classes of anti-hyperlipidemic agents
with high dosage is frequently needed. Increasing the number and
dosage of drugs enhances the possibility of developing medical
side effects but reduces patient's compliance. On the other hand,
discontinuation of treatment is not far-fetched [13]. At the present
time, introduction of some adjunctive therapies, such as herbal
therapies seems sensible.
Fenugreek seeds are polyphenol-rich foods that other studies
suggest, in concert with our results that may improve lipid proﬁle
and reduce risk factors possibly due the high values of polyphenol
in this herb. 4-Hydroxyisoleucine, as one of the Fenugreek
chemical compounds, can play an important role in TG reduction
that has been shown in previous studies [14,15]. Other phenolic
compounds like apigenin, caffeic acid, gallic acid, luteolin and
naringenin have been reported from this plant in previous studies
[16,17]. The essential oil analysis showed that the most abundant
essential oil is germacrene-D (28.2%) and the effects of this natural
sesquiterpene on hyperlipidemia have been reported in many
studies [8]. On the other hand, the antihyperlipidemic effects of
bicyclogermacrene as a potent natural product in hyperlipidemia
control in Casearia sylvestris were shown [18]. As a result, the
effects of fermentation products of Fenugreek ﬁbre such as short
chain fatty acids (SCFAs) (acetate, propionate, and butyrate) could
also be considered in the amelioration of diabetic and hyper-
lipidemic status. Fenugreek, like another herb that is phenolic-rich
herb could improve hyperlipidemia and the cardiovascular system.
Apigenin, luteolin and gallic acid from Sumac, Artichoke and
Hibiscus and their improvement effects in hyperlipidemia have
been reported in many studies [9,19,20]. The chemical compounds
reported from Fenugreek too [21]. As the results showed, after 8
weeks of Fenugreek in 8 g sachets, TG, TC, LDL and FBG signiﬁcantly
reduced. However, we did not identify any signiﬁcant difference in
BMI, HDL, LDL/HDL and TC/HDL before and after the intervention in
F group. The reduction between before and after the intervention
in TG in F group was 7.55 mg/dl, while this reduction in P group was
1.07 mg/dl. In TC factor the reduction between before and after theintervention in F group was 2.01 mg/dl, while in P group 0.43 mg/dl
was increased. The reductions between before and after the
intervention in LDL and FBS in F group were 3.08 and 2.39 mg/dl,
respectively, and the reductions in P group were 0.05 and 0.48 mg/
dl respectively. The signiﬁcant differences between the reductions
in F and P group are completely clear. However, the differences
between two groups before and after the study in HDL, LDL/HDL,
TC/HDL and BMI were not signiﬁcant. Indeed, beneﬁcial antioxi-
dant effects of this herb could modulate the lipid proﬁles [22].
4. Conclusion
This clinical study showed that consumption of 8 g Fenugreek
seed powder per day in patients with borderline lipid proﬁles for
two months could improve serum TG, TC, LDL and FBG levels.
Without causing any considerable side effect, Fenugreek seeds
were shown to be an effective therapeutic adjuvant in hyperlipid-
emia. Furthermore, the effects of Fenugreek could be attributed to
phenolic compounds as the dominant constituents in this herb.
However, further research is required to clarify the mechanisms
behind these observations.
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